ERBB2 and glioblastoma: In one of these studies, HER2-specific CAR-modified virus-specific T cells (VSTs) were tested in 17 patients with progressive HER2-positive glioblastomas: of the 16 patients evaluable, one had a partial response, seven had stable disease for 8 weeks to 29 months and eight progressed after T cell infusions [379].